Infection has so far been a major cause of morbidity and mortality in neutropenlc cancer patients. The risk of infection correlates with the degree and the duration of neutropenia. Prevention of infection is an aim which can be achieved in some instances by selective deconatmination.
For selective decontamination, 27 patients received 500 mg ciprofloxacin twice daily orally alone or in combination with nystatin, ketoconazole or amphoterlcin B. The patients suffered from acute nonlymphoblastic leukemia (n=16), acute lymphoblastic leukemia (n=7), blastic crisis of chronic myelogenous leukemia (n=1) and other tumors (n=3). The median duration of application of ciprofloxacin was 19 days with a range of 4 to 60 days. Under ciprofloxacin, fever did not appear in 14 patients, temperature over 38~ was observed in 13 cases. 5 of these patients had fungal infections, in 8 patients the origin of fever was unknown. 4 patients were treated additionally with systemic broad spectrum antibiotics; in 8 patients, broad spectrum antibiotics were given instead of ciprofloxacin.
Elevated enzyme values at the start decreased during selective decontamination. In conclusion, ciprofloxacin is suited for selective decontamination in neutropenic patients. ( CMML n=l, RAEB n=2~ RAEB-T n:l ) were treated with LD Ara-C. AML patients could be devided into3 categories (1) de novo AML n=10 (2) AML in relapse n=3 and (3) AML secondary to MDS n=7. The median age of the AML group was 67 years (range: 41 -80). To make possible out-patient care s~c. application of Ara-C at doses of 10 mg/m~/12h was chosen. Therapy was continued for 8 -21 days. All patients responding to LD Ara-C developed bone marrow hypoplasia and pancytopenia. Therapy had to be interrupted in 14 cases because of progressive thrombocytopenia leading to intracerebral bleeding in i patient with RAEB. CR was obtained in 4 patients with de novo AML. Duration of CR was 6+~4~4~9 months. PR was achieved in i patient with postmyelodysplastic AML. Presently (median time of observation 9 mo.,range 6 -20 mo.) 10 patients are still alive. Exept from the case mentioned above the other patients died of progression of leukemia. In summary our results show that CR rate and duration of AML patients treated with LD Ara-C is inferior to results of conventional aggressive chemotherapy. Therefore this regimen should be used only for patients in whom aggressive chemotherapy is contradicted. According to recent pharmacokinetic studies low efficiency and high rate of bone marrow hypoplasia might De due to s.c. administration.
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5 OLD PATIF~ WITH AOJTE ALEUCAF241C LEUOOSIS P. Beck, H. Gallenkamp Introduction: Typical acute leucoses are rarely to observe in elder people, even less the aleucaemic variations. After we had studied some paneyto penias, anemias and thrombocytopenias of unknown reason without success ~ decided to inspect regularly the bone marrow when some of these peripheral blood alterations could he se~. Within 5 rmmths 5 patients with acute aleucaemic leucaemias could be discovered. All patients were elder than 66 years. In the peripheral blood blast cells could not be fotmd. 1.163 Abdominal ultrasound, X-ray of the chest and other technical and blood examinations were normal. 2 patients are still alive, they get busulfan drugs. Pat. 2 -4 died after i0 days on the average. All diagnoses have been controlled by extem hematologists via bone marrow cytolngy/histology and peripheral blood smears. Discussion: Perhaps in elder patients the sequestration of blast cells is disturbed at the hone marrow barrier, perhaps the blast cell pepulations have a very short termed life in the peripheral blood. An acute alancaemic leucesis se~s to be more often in these patients. The ~e system may he less effective to prevent entering viral infectiorL~ which induce blast cell formation. This ~ system is less effective to attack these blast ce] Is as well. Thus aleucaemic leucosis could mean that blast cells are not "forced" to leave the bone marrow. Anemias, thrombocyto penias or pancytopenias in elder patients should be ex~ninad to exclude aleucaemic leucosis.
Inaere Abteiltmg, Ev. Krar~-J1aus Witten, Pferdebachstr.27 I)-5810 Wit tea Localized painful lesions of the bones and pathologic fractures are frequent in multiple myeloma. For these patients chemotherapy alone is insufficient. Additional local treatment modalities such as radiotherapy or surgery are necessary, in 94% of our patieL• radiotherapy was indicated due to localized severe pain, which was accompanied in 35% by osteolytic lesions, pathologic fractures or neurologic disturbances. 85 patients (55% males, 45% females, mean age: 59 years) have been irradiated with a 60-Co-or 437-Cs-source.
All received simultaneous chemotherapy.
The most common treated region was the spine (54%) followed by the thoracic wall (21%) and pelvis (~4%). 54% of the patients needed irradiation of more than one site during illness. After doses of at least 24 Gy 8q% of all patieLits were free or relieved of pain. Doses of more than 30 Gy were more effective and led to a higher percentage of asymptomatic patients. Following incomplete surgery of epidural tumours radiotherapy could permanently improve neurologic symptoms mildly to completely in ~0 of 44 cases. Recalcification of osteolytic lesions occured in 42 of 46 patients when doses higher than 24 Gy were given. The mean survival period of all patients after diagnosis was 36 months~ the 5-and ~O-year survival rates were 34% and 90% respectively. For long-term relievanee of pain and neurologic deficits as well as a potential recalcification of osteolytic lesions we recommend the administration of target volume doses of 25-30 Gy in 3-4 weeks.
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